Risk factors for RhD immunisation despite antenatal and postnatal anti-D prophylaxis

BJOG. 2009 Sep;116(10):1307-14. doi: 10.1111/j.1471-0528.2009.02244.x. Epub 2009 Jun 17.

Abstract

Objective: To identify risk factors for Rhesus D (RhD) immunisation in pregnancy, despite adequate antenatal and postnatal anti-D prophylaxis in the previous pregnancy. To generate evidence for improved primary prevention by extra administration of anti-D Ig in the presence of a risk factor.

Design: Case-control study.

Setting: Nation-wide evaluation of the Dutch antenatal anti-D-prophylaxis programme.

Cases: 42 RhD-immunised parae-1, recognised by first-trimester routine red cell antibody screening in their current pregnancy, who received antenatal and postnatal anti-D Ig prophylaxis (gifts of 1000 iu) in their first pregnancy.

Controls: 339 parae-1 without red cell antibodies.

Methods: Data were collected via obstetric care workers and/or personal interviews with women.

Main outcome measure: Significant risk factors for RhD immunisation in multivariate analysis.

Results: Independent risk factors were non-spontaneous delivery (assisted vaginal delivery or caesarean section) (OR 2.23; 95% CI:1.04-4.74), postmaturity (>or=42 weeks of completed gestation: OR 3.07; 95% CI:1.02-9.02), pregnancy-related red blood cell transfusion (OR 3.51; 95% CI:0.97-12.7 and age (OR 0.89/year; 95% CI:0.80-0.98). In 43% of cases, none of the categorical risk factors was present.

Conclusions: In at least half of the failures of anti-D Ig prophylaxis, a condition related to increased fetomaternal haemorrhage (FMH) and/or insufficient anti-D Ig levels was observed. Hence, RhD immunisation may be further reduced by strict compliance to guidelines concerning determination of FMH and accordingly adjusted anti-D Ig prophylaxis, or by routine administration of extra anti-D Ig after a non-spontaneous delivery and/or a complicated or prolonged third stage of labour.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Case-Control Studies
  • Female
  • Hematologic Agents / therapeutic use*
  • Humans
  • Isoantibodies / administration & dosage
  • Isoantibodies / therapeutic use*
  • Netherlands
  • Postnatal Care
  • Pregnancy
  • Pregnancy Complications, Hematologic / etiology
  • Pregnancy Complications, Hematologic / prevention & control*
  • Pregnancy Trimester, First
  • Prenatal Care
  • Rh Isoimmunization / etiology
  • Rh Isoimmunization / prevention & control*
  • Rho(D) Immune Globulin
  • Risk Factors
  • Secondary Prevention

Substances

  • Hematologic Agents
  • Isoantibodies
  • RHO(D) antibody
  • Rho(D) Immune Globulin